Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442501 in healthy adults
NCT05846009Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in achondroplasia (ACH) comparing SAR442501 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events/treatment-emergent adverse events/adverse events of special interest. Started Nov 2020; status: completed.
02
Drugs
SAR442501
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05846009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846009.